Midatech Pharma Inc. (NASDAQ: MTP) stock surged by 2% at last close while the MTP stock price gains by 71.08% in the pre-market trading session. Midatech Pharma is a medication delivery technology business that aims to improve medicine’s bio-delivery and bio-distribution.
What is happening?
MTP announces groundbreaking in vitro results demonstrating Q-ability Sphera’s to synthesize proteins into long-acting injectable medicines, as well as substantial progress on a number of other projects.
When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.
Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored
Read More
MTP has closed down its Bilbao operations, halving its monthly cash burn rate, and pivoted from a majorly singular focus on one Phase III ready asset to ‘multiple shots on goal’ with a broadened pipeline of nine earlier stage initiatives in the 13 months since the declaration of a Strategic Review. MTP’s goal is to get each program to proof of concept level before looking for licensing partners to help with subsequent stages of research, production, and commercialization.
MTP’s Q-Sphera technology encapsulates medicines in polymer-based bioresorbable microspheres that may be administered into the body to build depots that release the medication over a predicted, sustained period ranging from one week to many months.
One such technique is:
Since biologic products like mAbs and other high molecular weight proteins are fragile and readily denatured in manufacturing, there are no authorized long-acting injectable formulations. MTP has been working on an exemplary mAb and has proven in vitro encapsulation of the mAb as well as functional integrity and antigen-binding.
However,
These findings, according to MTP, have the ability to open up a lot of doors for its Q-Sphera technology. Protein-based medications make up a large portion of today’s medicines, and their reformulation into long-acting injectables might bring considerable benefits to patients, clinicians, and payers. In 2020, the top ten mAbs had worldwide sales of $74.9 billion1 and all mAbs had worldwide sales of $154 billion.
MTP’s next steps will be to improve the medication loading and dissolution profiles of encapsulated mAbs. In the meanwhile, MTP is reviewing a number of high-value mAb therapies for possible inclusion in its own pipeline, as well as replicating the results found in this exemplar mAb.